Arbutus Biopharma
ABUS
51 hedge funds and large institutions have $81.7M invested in Arbutus Biopharma in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 13 closing their positions.
91% more call options, than puts
Call options by funds: $469K | Put options by funds: $246K
7% less funds holding
Funds holding: 55 → 51 (-4)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
61% less capital invested
Capital invested by funds: $212M → $81.7M (-$131M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$4.22M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.51M |
| 3 |
Renaissance Technologies
New York
|
+$1.35M |
| 4 |
SCM
Suffolk Capital Management
New York
|
+$706K |
| 5 |
Primecap Management
Pasadena,
California
|
+$510K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$97.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$4.21M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.66M |
| 4 |
B
Bailard
Foster City,
California
|
-$1.31M |
| 5 |
Millennium Management
New York
|
-$830K |
ABUS Hedge Fund Activity: Q4 2015 in Review
51 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2015, worth a combined $81.7M — down 61% from $212M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ABUS and 9 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $4.22M. The largest seller was QVT Financial, exiting entirely with an estimated $97.5M sold.
- 51 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2015, down from 55 in Q3 2015.
- Funds reported $81.7M of Arbutus Biopharma stock for Q4 2015, down 61% quarter-over-quarter.
- 9 funds opened new Arbutus Biopharma positions in Q4 2015 and 13 closed out, a net change of -4 holders.
- The largest Arbutus Biopharma buyer in Q4 2015 was Bank of Montreal, an estimated $4.22M added.
- The largest Arbutus Biopharma seller in Q4 2015 was QVT Financial, an estimated $97.5M sold.
Based on aggregated 13F filings for Q4 2015.